Madrigal Pharmaceuticals, Inc. · NASDAQ:MDGL
Madrigal Pharmaceuticals — J.P. Morgan 43rd Annual Healthcare Conference (January 2025)
13 slides from Madrigal Pharmaceuticals's conference presentation, January 2025
Slide 1: J.P. Morgan 43rd Annual Healthcare Conference
J.P. Morgan 43rd Annual Healthcare Conference January 2025 NASDAQ: MDGL
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal’s beliefs and assumptions and on information currently available to it but are subject to
Slide 3: Our Purpose: Lead the fight against MASH
Our Purpose Lead the fight against MASH. #1 cause of liver- related death #1 cause of liver transplants #2 cause of liver transplants for women for men 3
Slide 4: Rezdiffra: Changing Patients’ Lives
Rezdiffra: Changing Patients’ Lives Jennifer was diagnosed with F2 MASH in 2021 and prescribed Rezdiffra in August 2024. Living with MASH felt like having a time bomb in my body. Rezdiffra gave me hope – and my life back. 4
Slide 5: 2024 was an Incredible Year for Madrigal
2024 was an Incredible Year for Madrigal Built expert leadership and commercial teams Phase 3 data in New England Journal of Medicine Rezdiffra launch: Landmark FDA Establishing a foundational therapy approval of Rezdiffra on March 14, 2024 Guidelines updated to include Rezdiffra as first-line thera
Slide 6: We are Building Toward a Blockbuster Medicine
We are Building Toward a Blockbuster Medicine Net Sales*: Generating Strong Uptake Patients on Rezdiffra: Steadily Adding Early in the Launch New Patients FY24 Net Sales: $177M-$180M >11,800 $100M-$103M $62.2M >6,800 $14.6M >2,000 2Q 3Q 4Q 2Q 3Q 4Q Rezdiffra launch is tracking in line with other top
Slide 7: Rezdiffra: Foundational Therapy in MASH with Exceptional Profile
Rezdiffra: Foundational Therapy in MASH with Exceptional Profile Liver directed MOA Highly effective Once daily oral pill Well tolerated THR-β agonist targets Halts/improves liver stiffness Differentiated ease Positive real-world results underlying causes of MASH in 91% of patients at 3 years of adm
Slide 8: Rezdiffra is the First and Only MASH Therapy
Rezdiffra is the First and Only MASH Therapy – Launching in an Attractive Specialty Market 315,000 • Current Rezdiffra F2/F3 target market patients • F2/F3 patients diagnosed and seeing a treating specialist <4% Patients on Rezdiffra as of YE24 8
Slide 9: Rezdiffra has Multiple Paths to Success – Competition to Accelerate Market Expansion
Rezdiffra has Multiple Paths to Success – Competition to Accelerate Market Expansion Awareness Screening Diagnosis Treatment High GLP-1 discontinuation rates1 Competitive entrant target market2 315K Current Rezdiffra F2/F3 target market <4% Patients on Rezdiffra as of YE24 1. Novo Nordisk: Investor
Slide 10: Additional Catalysts to Accelerate Rezdiffra Growth
Additional Catalysts to Accelerate Rezdiffra Growth Geographic Expansion Indication Expansion Tracking to mid-2025 CHMP opinion Completed enrollment in MAESTRO-NASH EU launch on schedule for 2H25, OUTCOMES trial pending EMA approval Rezdiffra has potential to be Hired Head of International first med
Slide 11: Madrigal: A Unique Investment Opportunity with Rezdiffra Poised for Blockbuster Success
Madrigal: A Unique Investment Opportunity with Rezdiffra Poised for Blockbuster Success Madrigal is the leader in Rezdiffra’s first-to-market Delivering on a highly Expanding leadership MASH, a market in its status can provide a successful U.S. Rezdiffra position to build long-term infancy sustainab
Slide 12: Outstanding 2024 Builds a Strong Foundation for 2025 and Beyond
Outstanding 2024 Builds a Strong Foundation for 2025 and Beyond 4Q24 FY24 Cash $100M-$103M $177M-$180M ~$931M net sales* 4Q24 net sales* FY24 as of YE24 More than 11,800 patients on Rezdiffra *Fourth quarter and full-year 2024 financial results are preliminary, unaudited, subject to adjustment, and
Slide 13: J.P. Morgan 43rd Annual Healthcare Conference
J.P. Morgan 43rd Annual Healthcare Conference January 2025 NASDAQ: MDGL
Madrigal Pharmaceuticals — J.P. Morgan 43rd Annual Healthcare Conference (January 2025) on 6ix